Ex-vivo and in-vivo evaluation of nanostructured lipid carrier loaded with gemcitabine and paclitaxel in A549 lung cell for management of resistant cancers
Abstract
The combination of gemcitabine (GEM) and paclitaxel (PTX) are effective anti-cancer regimens due to their different mechanisms of action and partially non-overlapping toxicities. The present study aimed to elucidate a potential effect of folic acid-conjugated-Gemcitabine-Paclitaxel-loaded nanostructured lipid carriers (FA-GEM-PTX-NLCs) on the proliferation of cancer cell lines A549 for the management of resistant cancer. Cell uptake of NLCs in A549 cell lines was carried out with fluorescent dye, and Fluorescein isothiocyanate loaded NLCs (FITC-NLCs). Flow cytometry showed that FA-PTX-GEM-NLCs exhibited enhanced cellular uptake via folate receptor-mediated endocytosis. Cytotoxic effect (GI50) of formulations was measured by MTT assay method using A549 cells. Cytotoxicity results reveal that the GI50 of FA-GEM-PTX-NLCs was 2.16 μg/mL, which is three times less than the GI50 (6.48 μg/mL) GEM-PTX-NLCs. Furthermore, data obtained from the pharmacokinetics study explored the extended half-life and higher serum concentration of GEM and PTX when delivered through FA-PTX-GEM-NLCs compared to PTX-GEM-NLCs and free drugs. Tumor growth inhibition results advocate for the higher anti-tumor activity of FA-GEM-PTX-NLCs in A549 cell line induced tumor-bearing Balb/c mice by estimating tumor burden. In conclusion, the novel folic acid conjugated NLCs loaded with GEM and PTX could be used as a potential chemotherapeutic formulation for cancer management.
Keywords:
Gemcitabine, Paclitaxel, nanostructured lipid carriers, combination chemotherapy, folic acid, A459 cell line.DOI
https://doi.org/10.25004/IJPSDR.2021.130407References
Singh MS, Tammam SN, ShetabBoushehri MA, Lamprecht A. MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. Pharmacological Research. 2017;126:2–30. Available from: doi:10.1016/j.phrs.2017.07.023
Kydd J, Jadia R, Velpurisiva P, Gad A, Paliwal S, Rai P. Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems. Pharmaceutics. 2017;9(4):46. Available from: doi:10.3390/pharmaceutics9040046
Van Moorsel CJ, Peters GJ, Pinedo HM. Gemcitabine: Future Prospects of Single-Agent and Combination Studies. Oncologist. 1997;2(3):127-134.Available from: PMID: 10388042
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Annals of oncology : official journal of the European Society for Medical Oncology. 2006;7:7–12. Available from: doi:10.1093/annonc/mdj941
Rowinsky EK, Donehower RC. Paclitaxel (TAXOL). The New England journal of medicine.1995;332(15):1004–1014. Available from: doi. org/10.1056/NEJM199504133321507
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature reviews. Cancer. 2004;4(4):253–265.Available from: doi. org/10.1038/nrc1317
Douillard JY, Lerouge D, Monnier A, Bennouna J, Haller AM, Sun XS, Assouline D, Grau B, Rivière A. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. British Journal of Cancer. 2001;84(9):1179–1184.Available from: doi.org/10.1054/ bjoc.2001.1784
Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ, Pinedo HM, Peters GJ.Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. British Journal of Cancer. 2000;83(8):1069–1076.Available from: doi.org/10.1054/ bjoc.2000.1399
Lei M, Sha S, Wang X, Wang J, Du X, Miao H, Zhu Y. Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer. RSC Advances. 2019;9(10): 5512–5520.Available from: doi.org/10.1039/C9RA00276F
Morton SW, Lee MJ, Deng ZJ, Dreaden EC, Siouve E, Shopsowitz KE, Shah NJ, Yaffe MB, Hammond PT. A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways. Science Signaling.2014;7(325): ra44–ra44.Available from: doi.org/10.1126/ scisignal.2005261
Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Advanced Drug Delivery Reviews. 2016;98:19–34.Available from: doi.org/10.1016/j. addr.2015.10.022
Bastiancich C, Bozzato E, Luyten U, Danhier F, Bastiat G, Préat V. Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment. International journal of pharmaceutics. 2019;559:220–227. Available from: doi.org/10.1016/j.ijpharm. 2019.01.042
Pushpalatha R, Selvamuthukumar S, Kilimozhi D. Nanocarrier mediated combination drug delivery for chemotherapy – A review. Journal of Drug Delivery Science and Technology. 2017;39:362–371. Available from: doi.org/10.1016/j.jddst.2017.04.019
Liang Y, Tian B, Zhang J, Li K, Wang L, Han J, Wu Z. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer. International Journal of Nanomedicine. 2017;12:1699–1715.Available from: doi.org/10.2147/IJN.S121262
Di H, Wu H, Gao Y, Li W, Zou D, Dong C. Doxorubicin and cisplatin loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug development and industrial pharmacy. 2016;42:2038–43.Available from: doi.org/10.1080/03639045.201 6.1190743
Dong Z, Gong H, Gao M, Zhu W, Sun X, Feng L, Fu T, Li Y, Liu Z. Polydopamine Nanoparticles as a Versatile Molecular Loading Platform to Enable Imaging-guided Cancer Combination Therapy. T heranost ic s. 2016;6(7 ):1031–1042 . Available f rom: doi. org/10.7150/thno.14431
Zhang J, Zhang P, Zou Q, Li X, Fu J, Luo Y, Liang X, Jin Y. Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment . Molecules. 2018;23:2906. Available from: doi. org/10.3390/molecules23112906
Lin T, Fang Q, Peng D, Huang X, Zhu T, Luo Q. PEGylated non-ionic surfactant vesicles as drug delivery systems for Gambogenic acid. Drug delivery. 2013;20:277–84.Available from: doi.org/10.3109/1 0717544.2013.836618
Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X.Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of nonsmall cell lung cancer. Biomaterials. 2014;35:6118–29.Available from: doi.org/10.1016/j. biomaterials.2014.04.034
Wang YH, Zhang JH, Li B, Li M, Xiuwen W. Lung cancer combination therapy: Co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug delivery. 2016;23:1398– 1403.Available from: doi.org/10.3109/10717544.2015.1055619
Chen Z, Wu X. Salidroside attenuates high glucose-induced apoptosis in human umbilical vein endothelial cells via activating the Ca(2)+/ CaM/CAMKIIδ/eNOS pathway. ZhonghuaXinXue Guan Bing ZaZhi. 2014;42(4):327-33.Available from: PubMed PMID: 24924461.
Chou TC. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research. 2010;70(2):440– 446.Available from: doi.org/10.1158/0008-5472.CAN-09-1947
Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM. Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Delivery. 2015;22:647–651.Available from: doi.org/10.3109/10717 544.2013.860502
Jain A, Jain A, Garg NK, Tyagi RK, Singh B, Katare OP, Webstere TJ, Soni V. Surface engineered polymeric nanocarriers mediate the delivery of transferrin–methotrexate conjugates for an improved understanding of brain cancer. ActaBiomaterialia. 2015;24:140– 151.Available from: doi.org/10.1016/j.actbio.2015.06.027
Wang F, Wang Y, Ma Q, Cao Y, Yu B. Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics. Artificial cells, nanomedicine, and biotechnology. 2016;45(8):1530– 1538.Available from: doi.org/10.1080/21691401.2016.1260578
Chen J, Li S, Shen Q, He H, Zhang Y. Enhanced cellular uptake of folic acid–conjugated PLGA–PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug development and industrial pharmacy. 2011; 37(11):1339–1346.Available from: doi.org/10.31 09/03639045.2011.575162
Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of nonsmall cell lung cancer. Biomaterials. 2014;35:6118–29.Available from: doi.org/10.1016/j. biomaterials.2014.04.034
Zhang BF, Xing L, Cui PF, Wang FZ, Xie RL, Zhang JL, Zhang M, He YJ, Lyu JY, Qiao JB, Chen BA, Jiang HL.Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine. Biomaterials. 2015;61:178– 189.Available from: doi.org/10.1016/j.biomaterials.2015.05.027
Chen S, Zhao X, Chen J, Chen J,Kuznetsova L, Wong SS, Ojima I. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjugate Chemistry. 2010;21(5):979-987.Available from: doi.org/10.1021/bc9005656
Published
Abstract Display: 547 
PDF Downloads: 411 
